Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Channelopathy Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNA1 Extracellular Loop (ECL) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View KCNA1 Products |
| Gene Delivery | KCNA1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Crucial for preserving native 6-TM conformation. |
View KCNA1 Products |
| Benchmark Ab | Anti-KCNA1 Recombinant Antibody Recombinant positive control for flow cytometry and functional blocking. |
View KCNA1 Products |
| Validator | KCNA1 siRNA Set For knockdown verification in functional assays. |
View KCNA1 Products |
| Related Target A | KCNA2 Subfamily homolog. Essential for off-target selectivity screening to prevent neurological toxicity. |
View KCNA2 Products |
| Related Target B | KCNA3 Subfamily homolog. Crucial counter-screening target for neuro-specific channel modulators. |
View KCNA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preservation of 6-TM Native Tetrameric Conformation | High-titer Lentivirus Premade Particles for stable, functional cell line generation. |
| Subfamily Counter-Screening (Kv1.1 vs Kv1.2/Kv1.3) | Sequence-verified KCNA2 and KCNA3 expression vectors and recombinant proteins available. |
| Lack of Controls | Functional benchmark antibodies and validated positive controls included |
| False Positives | Validated siRNA sets included for target-specific knockdown verification |
Live KCNA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNA1 (Kv1.1) therapeutics is intensifying, with major players shifting focus from traditional small-molecule blockers to highly selective positive allosteric modulators (PAMs) and targeted biologics. As first-generation therapies for episodic ataxia type 1 (EA1) and epilepsy reach clinical validation, the next wave of R&D is targeting subtype-selective monoclonal antibodies and peptide-toxin conjugates to bypass the blood-brain barrier and minimize off-target cardiac effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAMs) | Neuro-focused Biopharma | Epilepsy, Episodic Ataxia Type 1 (EA1) | High-throughput Screening (Need Lentivirus for stable cell lines) |
| Monoclonal Antibodies | Immunotherapy & Neuro-specialists | Neuropathic Pain, Autoimmune Neuropathy | Epitope Mapping (Need Recombinant Extracellular Loops) |
| Peptide Toxins / Conjugates | Venom-based Drug Developers | Multiple Sclerosis, Neuroinflammation | Selectivity Screening (Need KCNA1 vs KCNA2/3 Homolog Panels) |